Aquestive(US:AQST)2024-03-06 13:01Financial Performance - The company exceeded its revenue and Non-GAAP Adjusted EBITDA guidance[5] - A $45 million debt refinancing resulted in approximately $28 million cash savings through June 2025[5] - The company finished the year with approximately $24 million in cash[5, 9] Anaphylm (epinephrine) sublingual film - The company is on track for submission of a New Drug Application (NDA) before year end 2024[6] - Positive top-line data was reported from pilot studies in 2023[6] - A pivotal trial commenced in December 2023, with top-line data expected in March 2024[6, 9] Libervant (diazepam) buccal film - An NDA was submitted for Libervant for patients between the ages of two and five years old[7] - The PDUFA action date is April 28, 2024[7] 2024 Outlook - The company expects total revenues of approximately $48 to $51 million[26] - The company anticipates a Non-GAAP adjusted EBITDA loss of approximately $22 to $26 million[26]